Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.

Tytuł:
Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.
Autorzy:
Menghrajani K; Memorial Sloan Kettering Cancer Center, USA. Electronic address: .
Zhang Y; Memorial Sloan Kettering Cancer Center, USA.
Famulare C; Memorial Sloan Kettering Cancer Center, USA.
Devlin SM; Memorial Sloan Kettering Cancer Center, USA.
Tallman MS; Memorial Sloan Kettering Cancer Center, USA; Weill-Cornell Medical College, USA.
Źródło:
Leukemia research [Leuk Res] 2020 Nov; Vol. 98, pp. 106453. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Oxford ; New York : Pergamon Press
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Breast Neoplasms*/pathology
Chromosomes, Human, Pair 11*/genetics
Chromosomes, Human, Pair 11*/metabolism
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/pathology
Neoplasms, Second Primary*/drug therapy
Neoplasms, Second Primary*/genetics
Neoplasms, Second Primary*/metabolism
Neoplasms, Second Primary*/pathology
Translocation, Genetic*
Anthracyclines/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Chromosomes, Human, Pair 19/genetics ; Chromosomes, Human, Pair 19/metabolism ; Chromosomes, Human, Pair 9/genetics ; Chromosomes, Human, Pair 9/metabolism ; Female ; Humans ; Male ; Middle Aged
References:
Leukemia. 2001 Jun;15(6):987-9. (PMID: 11417488)
Blood. 2002 Jul 1;100(1):29-35. (PMID: 12070004)
Semin Oncol. 2008 Aug;35(4):418-29. (PMID: 18692692)
Leukemia. 2015 Dec;29(12):2375-81. (PMID: 26082270)
Blood. 2011 Jun 30;117(26):7102-11. (PMID: 21551233)
Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9. (PMID: 1720549)
Cancer. 2010 Nov 1;116(21):5012-21. (PMID: 20629023)
J Clin Oncol. 2013 Jan 1;31(1):95-103. (PMID: 23008312)
Leukemia. 2013 Apr;27(4):836-42. (PMID: 23135353)
Blood. 2003 Oct 1;102(7):2395-402. (PMID: 12805060)
Nat Rev Cancer. 2007 Nov;7(11):823-33. (PMID: 17957188)
Blood. 2011 Feb 17;117(7):2137-45. (PMID: 21127174)
N Engl J Med. 2016 Jun 9;374(23):2209-2221. (PMID: 27276561)
J Clin Oncol. 2003 Dec 15;21(24):4642-9. (PMID: 14673054)
Blood. 1998 Oct 1;92(7):2322-33. (PMID: 9746770)
Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254)
J Clin Oncol. 2009 Jun 20;27(18):3000-6. (PMID: 19380453)
Leukemia. 2018 Feb;32(2):273-284. (PMID: 28701730)
Blood. 2010 Jul 22;116(3):354-65. (PMID: 20385793)
Blood. 2009 Sep 17;114(12):2489-96. (PMID: 19528532)
Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058)
Cell. 2007 Nov 16;131(4):633-6. (PMID: 18022353)
Br J Haematol. 2011 Nov;155(4):413-9. (PMID: 21910721)
Leukemia. 2016 Jul;30(7):1586-9. (PMID: 26669971)
Blood. 2000 Dec 15;96(13):4075-83. (PMID: 11110676)
Grant Information:
K12 CA184746 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS
Contributed Indexing:
Keywords: 11q23; AML; Cytogenetics; KMT2A; MLL; Therapy-related myeloid neoplasm
Substance Nomenclature:
0 (Anthracyclines)
Entry Date(s):
Date Created: 20201015 Date Completed: 20210118 Latest Revision: 20211102
Update Code:
20240105
PubMed Central ID:
PMC8384453
DOI:
10.1016/j.leukres.2020.106453
PMID:
33059120
Czasopismo naukowe
We described the clinical features and outcomes for 63 adult patients with acute myeloid leukemia (AML) with a translocation involving the 11q23 locus (MLL) who were treated at Memorial Sloan Kettering Cancer Center (MSK). The population included 40 female (63 %) and 23 male (37 %) patients, with a median age of 51 years old (range 18-82 years). Of the 31 patients who had had an antecedent malignancy, 14 (45 %) had had breast cancer or DCIS and 22 (71 %) had received anthracycline-based systemic chemotherapy. The translocation partner for the 11q23 rearrangement was identified in 60 of the 63 patients (95 %) studied. The distribution of translocation partners differed for those who had previously received cytotoxic chemotherapy. Most patients with therapy-related disease had a 9p22 or 19p13 partner, as compared to those with de novo disease (95 % vs. 68 %, p = 0.023). Of the 30 patients who received all therapy under observation, 15 (50 %) patients had de novo disease and 15 (50 %) had received antecedent chemotherapy. No significant difference in survival was observed between groups (p = 0.44). Twenty-two patients received induction as up-front therapy, of whom 11 (50 %) achieved CR / CRi. The achievement of CR / CRi with one course of induction was associated with improved OS, with a 6-month OS of 73 % as compared to 23 % for those who did not (p = 0.018). The achievement of CR / CRi with a single course of induction may be a marker of favorable survival in this subtype of high-risk AML. KEY POINT: Response to a single induction was associated with favorable survival in this population.
(Copyright © 2020. Published by Elsevier Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies